Valora Therapeutics uses its proprietary AbLec™ platform to decode glycan-mediated immune signaling pathways. By targeting the sugar code that governs cellular communication, the company develops immunotherapies aimed at restoring proper immune function. Their approach is applied to a broad range of diseases where immune dysregulation is a key factor.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and immune disease treatments often fail because they do not effectively address the communication breakdowns within the immune system. These communication defects hinder the body's ability to mount a proper immune response, limiting the efficacy of existing therapies.
Solution
Valora Therapeutics is developing a novel biological drug that leverages its proprietary AbLec platform to decode the "sugar code" of cellular and immune interactions. By understanding and manipulating these interactions, Valora aims to enhance immune signaling mechanisms and restore effective immune communication. This approach seeks to create transformative therapies for oncology and immune diseases by correcting the underlying communication defects that compromise immune responses. The AbLec platform unlocks new possibilities in immunotherapy by targeting the glycobiology of immune cells.
Target Audience
The primary target audience includes patients suffering from cancer and immune diseases, as well as healthcare providers seeking more effective treatment options.
Features
- AbLec platform: Decodes the sugar code of cellular and immune interactions.
- Biological drug development: Enhances immune signaling mechanisms.
- Targeted immunotherapy: Addresses communication defects in immune responses.
- Glycobiology focus: Targets the sugar code to unlock new therapeutic possibilities.